MEP13808A - Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders - Google Patents
Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disordersInfo
- Publication number
- MEP13808A MEP13808A MEP-138/08A MEP13808A MEP13808A ME P13808 A MEP13808 A ME P13808A ME P13808 A MEP13808 A ME P13808A ME P13808 A MEP13808 A ME P13808A
- Authority
- ME
- Montenegro
- Prior art keywords
- prevention
- treatment
- disorders
- mesoprogestins
- gynecological disorders
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 4
- 230000001419 dependent effect Effects 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 5
- 102000003998 progesterone receptors Human genes 0.000 abstract 3
- 108090000468 progesterone receptors Proteins 0.000 abstract 3
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 2
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 2
- 208000032843 Hemorrhage Diseases 0.000 abstract 2
- 206010027514 Metrorrhagia Diseases 0.000 abstract 2
- 206010034650 Peritoneal adhesions Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000000740 bleeding effect Effects 0.000 abstract 2
- 230000002980 postoperative effect Effects 0.000 abstract 2
- 239000002379 progesterone receptor modulator Substances 0.000 abstract 2
- 208000004145 Endometritis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 230000000708 anti-progestin effect Effects 0.000 abstract 1
- 239000003418 antiprogestin Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 208000007106 menorrhagia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 150000003146 progesterones Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38614199A | 1999-08-31 | 1999-08-31 | |
| PCT/US2000/023770 WO2001015679A2 (en) | 1999-08-31 | 2000-08-31 | Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP13808A true MEP13808A (en) | 2010-06-10 |
Family
ID=23524338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-138/08A MEP13808A (en) | 1999-08-31 | 2000-08-31 | Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1229906B1 (de) |
| JP (1) | JP2003535029A (de) |
| KR (3) | KR20080066095A (de) |
| AR (1) | AR025457A1 (de) |
| AT (1) | ATE375160T1 (de) |
| AU (1) | AU781840B2 (de) |
| BG (1) | BG65817B1 (de) |
| BR (1) | BR0014161A (de) |
| CA (1) | CA2382580C (de) |
| CO (1) | CO5200772A1 (de) |
| CZ (1) | CZ2002704A3 (de) |
| DE (1) | DE60036723T2 (de) |
| DK (1) | DK1229906T3 (de) |
| EA (1) | EA007854B1 (de) |
| EE (1) | EE05172B1 (de) |
| ES (1) | ES2295050T3 (de) |
| HR (1) | HRP20020267A2 (de) |
| HU (1) | HUP0202429A3 (de) |
| IL (1) | IL148416A0 (de) |
| LT (1) | LT5034B (de) |
| LV (1) | LV12941B (de) |
| ME (1) | MEP13808A (de) |
| MX (1) | MXPA02002191A (de) |
| NO (1) | NO20020999L (de) |
| NZ (1) | NZ517471A (de) |
| PE (1) | PE20010578A1 (de) |
| PL (1) | PL198790B1 (de) |
| PT (1) | PT1229906E (de) |
| RO (1) | RO122179B1 (de) |
| RS (1) | RS50283B (de) |
| SI (1) | SI20852B (de) |
| SK (1) | SK287192B6 (de) |
| UA (1) | UA78184C2 (de) |
| WO (1) | WO2001015679A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| ES2273061T3 (es) * | 2002-08-02 | 2007-05-01 | Schering Aktiengesellschaft | Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal. |
| US20040097591A1 (en) * | 2002-11-18 | 2004-05-20 | Kristof Chwalisz | Use of selective progesterone receptor modulators for the treatment of androgen deficiency |
| RU2301691C1 (ru) * | 2005-12-20 | 2007-06-27 | Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук | Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки |
| DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| RU2339392C1 (ru) * | 2007-05-21 | 2008-11-27 | Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий | Способ остановки маточных кровотечений в пубертатном периоде |
| US9592213B2 (en) * | 2009-06-17 | 2017-03-14 | National University Corporation Kumamoto University | Prophylactic and/or therapeutic agent for dysmenorrhea |
| US8399432B2 (en) * | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
| CN114728013A (zh) * | 2019-09-23 | 2022-07-08 | 斯坦福大学托管董事会 | 延长妊娠以及月经或妊娠的并发症的治疗方法 |
| US12426782B2 (en) | 2020-11-06 | 2025-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and temporal alignment methods for evaluation of gestational age and time to delivery |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3633244A1 (de) | 1986-09-26 | 1988-03-31 | Schering Ag | Antigestagene zur hemmung der uterinen prostaglandinsynthese |
| DE4332283A1 (de) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332284C2 (de) | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| US5576310A (en) * | 1994-09-20 | 1996-11-19 | Jenapharm Gmbh | 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds |
| EP1043325B1 (de) * | 1994-12-22 | 2004-06-16 | Ligand Pharmaceuticals Incorporated | Steroidrezeptor-Modulator Verbindungen und Methoden |
| US5696130A (en) * | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Tricyclic steroid receptor modulator compounds and methods |
| WO1996023503A1 (de) | 1995-02-02 | 1996-08-08 | Schering Aktiengesellschaft | Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| AU710139B2 (en) * | 1996-05-01 | 1999-09-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | 21-substituted progesterone derivatives as new antiprogestational agents |
| WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
| DE19809845A1 (de) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| WO2000042031A2 (en) * | 1999-01-14 | 2000-07-20 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| WO2000066590A2 (en) * | 1999-05-04 | 2000-11-09 | Ligand Pharmaceuticals, Inc. | Tetracyclic progesterone receptor modulator compounds and methods |
-
2000
- 2000-08-31 CO CO00065515A patent/CO5200772A1/es not_active Application Discontinuation
- 2000-08-31 IL IL14841600A patent/IL148416A0/xx unknown
- 2000-08-31 PL PL353930A patent/PL198790B1/pl not_active IP Right Cessation
- 2000-08-31 KR KR1020087016247A patent/KR20080066095A/ko not_active Withdrawn
- 2000-08-31 ME MEP-138/08A patent/MEP13808A/xx unknown
- 2000-08-31 UA UA2002032430A patent/UA78184C2/uk unknown
- 2000-08-31 WO PCT/US2000/023770 patent/WO2001015679A2/en not_active Ceased
- 2000-08-31 HR HR20020267A patent/HRP20020267A2/xx not_active Application Discontinuation
- 2000-08-31 CA CA002382580A patent/CA2382580C/en not_active Expired - Lifetime
- 2000-08-31 PT PT00957914T patent/PT1229906E/pt unknown
- 2000-08-31 ES ES00957914T patent/ES2295050T3/es not_active Expired - Lifetime
- 2000-08-31 NZ NZ517471A patent/NZ517471A/en unknown
- 2000-08-31 CZ CZ2002704A patent/CZ2002704A3/cs unknown
- 2000-08-31 DE DE60036723T patent/DE60036723T2/de not_active Expired - Lifetime
- 2000-08-31 SI SI200020042A patent/SI20852B/sl not_active IP Right Cessation
- 2000-08-31 PE PE2000000893A patent/PE20010578A1/es not_active Application Discontinuation
- 2000-08-31 RS YUP-140/02A patent/RS50283B/sr unknown
- 2000-08-31 EE EEP200200104A patent/EE05172B1/xx not_active IP Right Cessation
- 2000-08-31 AR ARP000104538A patent/AR025457A1/es unknown
- 2000-08-31 EP EP00957914A patent/EP1229906B1/de not_active Expired - Lifetime
- 2000-08-31 BR BR0014161-5A patent/BR0014161A/pt not_active Application Discontinuation
- 2000-08-31 DK DK00957914T patent/DK1229906T3/da active
- 2000-08-31 AU AU69466/00A patent/AU781840B2/en not_active Ceased
- 2000-08-31 HU HU0202429A patent/HUP0202429A3/hu unknown
- 2000-08-31 EA EA200200282A patent/EA007854B1/ru not_active IP Right Cessation
- 2000-08-31 AT AT00957914T patent/ATE375160T1/de not_active IP Right Cessation
- 2000-08-31 JP JP2001519893A patent/JP2003535029A/ja active Pending
- 2000-08-31 SK SK299-2002A patent/SK287192B6/sk unknown
- 2000-08-31 RO ROA200200229A patent/RO122179B1/ro unknown
- 2000-08-31 KR KR1020077011455A patent/KR100864547B1/ko not_active Expired - Fee Related
- 2000-08-31 KR KR1020027002790A patent/KR100755109B1/ko not_active Expired - Fee Related
-
2002
- 2002-02-26 BG BG106442A patent/BG65817B1/bg unknown
- 2002-02-28 MX MXPA02002191A patent/MXPA02002191A/es active IP Right Grant
- 2002-02-28 NO NO20020999A patent/NO20020999L/no not_active Application Discontinuation
- 2002-03-21 LT LT2002031A patent/LT5034B/lt not_active IP Right Cessation
- 2002-03-28 LV LVP-02-53A patent/LV12941B/lv unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120015917A1 (en) | Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy | |
| MEP38008A (en) | Drospirenone for hormone replacement therapy | |
| DK0792152T3 (da) | Fremgangsmåder til svangerskabsforebyggelse | |
| Fraser | Added health benefits of the levonorgestrel contraceptive intrauterine system and other hormonal contraceptive delivery systems | |
| MEP13808A (en) | Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders | |
| NO964155L (no) | Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger | |
| Soaje et al. | A modulatory role of endogenous opioids on prolactin secretion at the end of pregnancy in the rat | |
| Murray | Natural progesterone: what role in women’s health care | |
| Brązert et al. | Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology | |
| PL201898B1 (pl) | Zastosowanie antagonisty LH-RH w leczeniu endometriozy | |
| Ohara | Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma | |
| SK101395A3 (en) | Pharmaceutical anticonceptive agent and its use | |
| EP1462106A1 (de) | Pharmazeutishe Zusammensetzungen und Kits enthaltend 17-Betaestradiol und Progesteron zur Behandlung von Gynäcologischen Storungen | |
| EA200200285A1 (ru) | Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента композиций для заместительной гормональной терапии (згт) | |
| WO2003041719A1 (en) | Method of contraception in mammalian females and pharmaceutical kit for use in such method | |
| Liu et al. | Effect of some oral contraceptive steroids on the development of endometrial squamous metaplasia and cysts in rats | |
| BR0010070A (pt) | Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio | |
| Rojas et al. | 1Department of Obstetrics and Gynecology | |
| HRP20070360B1 (hr) | Drospirenon za hormonsku nadomjesnu terapiju | |
| HRP20020666A8 (en) | Drospirenone for hormone replacement therapy | |
| CN1450892A (zh) | 中孕酮(孕酮受体调节剂)用于治疗和预防激素依赖性良性妇科疾病 |